Literature DB >> 26601962

Neuroprotective Mechanisms Mediated by CDK5 Inhibition.

Gohar Mushtaq1, Nigel H Greig2, Firoz Anwar, Fahad A Al-Abbasi, Mazin A Zamzami, Hasan A Al-Talhi, Mohammad A Kamal.   

Abstract

Cyclin-dependent kinase 5 (CDK5) is a proline-directed serine/threonine kinase belonging to the family of cyclin-dependent kinases. In addition to maintaining the neuronal architecture, CDK5 plays an important role in the regulation of synaptic plasticity, neurotransmitter release, neuron migration and neurite outgrowth. Although various reports have shown links between neurodegeneration and deregulation of cyclin-dependent kinases, the specific role of CDK5 inhibition in causing neuroprotection in cases of neuronal insult or in neurodegenerative diseases is not wellunderstood. This article discusses current evidence for the involvement of CDK5 deregulation in neurodegenerative disorders and neurodegeneration associated with stroke through various mechanisms. These include upregulation of cyclin D1 and overactivation of CDK5 mediated neuronal cell death pathways, aberrant hyperphosphorylation of human tau proteins and/or neurofilament proteins, formation of neurofibrillary lesions, excitotoxicity, cytoskeletal disruption, motor neuron death (due to abnormally high levels of CDK5/p25) and colchicine- induced apoptosis in cerebellar granule neurons. A better understanding of the role of CDK5 inhibition in neuroprotective mechanisms will help scientists and researchers to develop selective, safe and efficacious pharmacological inhibitors of CDK5 for therapeutic use against human neurodegenerative disorders, such as Alzheimer's disease, amyotrophic lateral sclerosis and neuronal loss associated with stroke.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26601962      PMCID: PMC5002348          DOI: 10.2174/1381612822666151124235028

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  99 in total

Review 1.  Glycogen synthase kinase-3: properties, functions, and regulation.

Authors:  A Ali; K P Hoeflich; J R Woodgett
Journal:  Chem Rev       Date:  2001-08       Impact factor: 60.622

2.  CDK5 phosphorylates DRP1 and drives mitochondrial defects in NMDA-induced neuronal death.

Authors:  Arezu Jahani-Asl; En Huang; Isabella Irrcher; Juliet Rashidian; Naotada Ishihara; Diane C Lagace; Ruth S Slack; David S Park
Journal:  Hum Mol Genet       Date:  2015-05-22       Impact factor: 6.150

3.  Physiological levels of beta-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production.

Authors:  J M Price; X Chi; G Hellermann; E T Sutton
Journal:  Neurol Res       Date:  2001-07       Impact factor: 2.448

4.  Investigating the neuroprotective mechanism of action of a CDK5 inhibitor by phosphoproteome analysis.

Authors:  Frank Gillardon; André Schrattenholz; Bernd Sommer
Journal:  J Cell Biochem       Date:  2005-07-01       Impact factor: 4.429

5.  CDK5 serves as a major control point in neurotransmitter release.

Authors:  Sung Hyun Kim; Timothy A Ryan
Journal:  Neuron       Date:  2010-09-09       Impact factor: 17.173

6.  Truncation of CDK5 activator p35 induces intensive phosphorylation of Ser202/Thr205 of human tau.

Authors:  Mitsuko Hashiguchi; Taro Saito; Shin-ichi Hisanaga; Toshio Hashiguchi
Journal:  J Biol Chem       Date:  2002-09-10       Impact factor: 5.157

7.  Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models.

Authors:  Bénédicte Menn; Stéphane Bach; Teri L Blevins; Mark Campbell; Laurent Meijer; Serge Timsit
Journal:  PLoS One       Date:  2010-08-12       Impact factor: 3.240

Review 8.  Cyclin-dependent kinase 5 in amyotrophic lateral sclerosis.

Authors:  Minh Dang Nguyen; Jean-Pierre Julien
Journal:  Neurosignals       Date:  2003 Sep-Oct

9.  Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.

Authors:  Panagiotis Polychronopoulos; Prokopios Magiatis; Alexios-Leandros Skaltsounis; Vassilios Myrianthopoulos; Emmanuel Mikros; Aldo Tarricone; Andrea Musacchio; S Mark Roe; Laurence Pearl; Maryse Leost; Paul Greengard; Laurent Meijer
Journal:  J Med Chem       Date:  2004-02-12       Impact factor: 7.446

Review 10.  Cyclin-dependent kinases.

Authors:  Marcos Malumbres
Journal:  Genome Biol       Date:  2014       Impact factor: 13.583

View more
  22 in total

Review 1.  Gephyrin: a key regulatory protein of inhibitory synapses and beyond.

Authors:  Femke L Groeneweg; Christa Trattnig; Jochen Kuhse; Ralph A Nawrotzki; Joachim Kirsch
Journal:  Histochem Cell Biol       Date:  2018-09-27       Impact factor: 4.304

Review 2.  Kinase inhibitors: the road ahead.

Authors:  Fleur M Ferguson; Nathanael S Gray
Journal:  Nat Rev Drug Discov       Date:  2018-03-16       Impact factor: 84.694

3.  Editorial: Frontier Views in Designing Therapeutic Candidates for Management of Diverse Diseases.

Authors:  Mohammad A Kamal; Nigel H Greig
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

4.  N-Methyl-D-Aspartate Receptor Signaling-Protein Kinases Crosstalk in Cerebral Ischemia.

Authors:  Atilla Engin; Ayse Basak Engin
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Sustained (S)-roscovitine delivery promotes neuroprotection associated with functional recovery and decrease in brain edema in a randomized blind focal cerebral ischemia study.

Authors:  Estelle Rousselet; Anne Létondor; Bénédicte Menn; Yann Courbebaisse; Marie-Lise Quillé; Serge Timsit
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-01       Impact factor: 6.200

6.  Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development (Part C)).

Authors:  Mohammad A Kamal; Nigel H Greig
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

7.  Editorial: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Development.

Authors:  Mohammad A Kamal; Nigel H Greig
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

8.  Epibrassinolide prevents tau hyperphosphorylation via GSK3β inhibition in vitro and improves Caenorhabditis elegans lifespan and motor deficits in combination with roscovitine.

Authors:  Pinar Obakan Yerlikaya; Elif Damla Arısan; Ajda Coker Gurkan; Osman Orcun Okumus; Tugba Yenigun; Utku Ozbey; Melissa Kara; Narcin Palavan Unsal
Journal:  Amino Acids       Date:  2021-08-13       Impact factor: 3.520

9.  Indirubin Derivative 7-Bromoindirubin-3-Oxime (7Bio) Attenuates Aβ Oligomer-Induced Cognitive Impairments in Mice.

Authors:  Liping Chen; Chunhui Huang; Jieyi Shentu; Minjun Wang; Sicheng Yan; Fei Zhou; Zaijun Zhang; Chuang Wang; Yifan Han; Qinwen Wang; Wei Cui
Journal:  Front Mol Neurosci       Date:  2017-11-28       Impact factor: 5.639

10.  Cyclin-dependent kinase 5-mediated phosphorylation of chloride intracellular channel 4 promotes oxidative stress-induced neuronal death.

Authors:  Dong Guo; Wenting Xie; Pan Xiong; Huifang Li; Siqi Wang; Guimiao Chen; Yuehong Gao; Jiechao Zhou; Ye Zhang; Guojun Bu; Maoqiang Xue; Jie Zhang
Journal:  Cell Death Dis       Date:  2018-09-20       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.